MedTrace Logo

Efficacy Study of Vitamin D Supplementation to Meticillin Resistant Staphylococcus Aureus (MRSA) Carriers

NCT02178488 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-01-23

No results posted yet for this study

Summary

The purpose of this study is to treat persistent MRSA carriers with vitamin D supplementation during a 12 month to see if the number of MRSA positive patients can be reduced.

Conditions

  • Methicillin Resistant Staphylococcus Aureus
  • Vitamin D3 Deficiency

Interventions

DRUG

Cholecalciferol

Cholecalciferol 4000 IU/day for 12 months

OTHER

Placebo

Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months

Sponsors & Collaborators

  • Peter Bergman

    lead OTHER

Principal Investigators

  • Gudrun Lind, M.D PhD · Karolinska University Hospital, Solna. Department of Infectious Diseases

  • Peter Bergman, M.D PhD · Karolinska University Hospital Huddinge, Department of Infectious Diseases

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02178488 on ClinicalTrials.gov